Skip to content
Subscriber Only

Bain Considers Options for Waystar Including Sale

  • Health tech business could be valued at more than $3 billion
  • Waystar may attract interest from companies like Oracle, Visa
biotech lab healthcare biohealth
Photographer: Martin Divisek/Bloomberg

Bain Capital is considering options for Waystar that could lead to a sale of the health-care technology company, according to people familiar with the matter.

Bain, which created the business by combining Navicure Inc. and ZirMed in 2017, has held early stage discussions about a potential sale of the business, said the people, asking not to be identified as the discussions are private. Waystar could attract interest from companies such as Oracle Corp. and Visa Inc., the people said.